Luminex Corp

Luminex Corp, a foreign-owned manufacturer of multiplex diagnostic solutions and in vitro diagnostic products, operates as a prime contractor delivering reagents, assay kits, calibration equipment, maintenance services, and diagnostic instruments to federal agencies across civilian and defense sectors. The company competes full-and-open without set-aside designations, holding a portfolio of 1,321 awards (1,319 as prime, 2 as sub) valued at $164.2 million combined potential value with $76.5 million obligated to date. Luminex is a subsidiary of Diasorin Inc., a foreign-owned manufacturer, and maintains a subsidiary operation (Luminex Molecular Diagnostics, Inc.).

Luminex's capability footprint centers on multiplex diagnostic platforms, reagents, and supporting laboratory services. The company manufactures proprietary instrument lines (MAGPIX, INTELLIFLEX, VERIGENE, xPONENT systems) and sells performance verification kits, calibration equipment, sheath fluids, microspheres, and assay panels including XTAG Cystic Fibrosis Kits, NxTAG Respiratory Pathogen Panels, and Salmonella serotyping assay kits. Representative work includes a $302.578 million delivery order from the Defense Logistics Agency's Medical Supply Chain for XTAG Cystic Fibrosis Kits (October 2025); a $248.758 million sole-source definitive contract with CDC Pittsburgh for multiplex analyte detection instruments not requiring laser calibration (August 2024); a $121.316 million BPA call from the Department of Veterans Affairs for PCR testing services to VA Pittsburgh Healthcare System (July 2026); a $76.722 million Naval Health Research Center purchase order for NxTAG Respiratory Pathogen Panel reagents and MAGPIX components (August 2025); and a $60.52 million sole-source CDC purchase order for two MAGPIX xPONENT Systems for biosafety level-3 laboratory operations (September 2025).

Customer concentration is dominated by defense and health agencies. The Defense Logistics Agency Troop Support Medical represents 302 awards at $51.8 million (31% of total dollar value), anchoring the portfolio; the Department of the Navy Bureau of Medicine and Surgery holds 83 awards at $16.3 million; the Department of the Air Force Materiel Command Wright Patterson Air Force Base carries 23 awards at $15.9 million; CDC Pittsburgh accounts for 119 awards at $4.1 million; and the Department of the Air Force Air Education and Training Command carries 56 awards at $4.9 million. These five customers account for 57% of combined potential value across 643 awards. NAICS concentration skews medical device and supply wholesale (313 awards) and analytical laboratory instrument manufacturing (248 awards).

Luminex's vehicle footprint centers on Defense Logistics Agency indefinite delivery structures and GSA Schedules. The IDC SPE2DH22D0002 (Defense Logistics Agency) generates 301 task orders at $3.7 million combined value; the GSA Schedule for In Vitro Diagnostics, Reagents, and Test Kits (FSS-65-VII) supports 37 task orders at $8.6 million; the GSA Multiple Award Schedule carries 21 task orders at $1.5 million; and two Air Force blanket purchase agreements (FA860119AA001 and FA301020A0002) total 32 task orders at $5.2 million combined. The company also holds three primary IDVs: a $5.762 million single-award BPA with the Department of the Air Force's 711th Human Performance Wing for Luminex reagents (issued February 2025, extending through January 2030); a $250,000 single-award IDC with USDA Veterinary Services for Salmonella serotyping assay kits (awarded December 2024, through December 2026); and a $519.140 million single-award BPA with Veterans Integrated Service Network 4 for PCR testing services to VA Pittsburgh Healthcare System (issued July 2023, extended to June 2028, with multiple calls issued July 2023, 2024, 2025, and 2026).

Activity has remained steady year-over-year—89 awards in 2022, 113 in 2023, 118 in 2024, 98 in 2025, with 29 awards recorded in the first two months of 2026. Twenty-two awards (combined potential value $1.5 million) reach ultimate completion within the next twenty-four months, representing moderate near-term recompete exposure. Luminex's first federal award dates to May 1999; the source carries 1,321 awards spanning through August 2026.

The company's subcontract footprint is negligible (2 total awards across the portfolio). Luminex holds a sub-award from the National Foundation for the Centers for Disease Control and Prevention under the Partnerships to Strengthen Health Security and Respond to Health Threats American Rescue Plan grant (March 2023), and a purchase-of-supplies sub-award from Battelle National Biodefense Institute under the Department of Homeland Security NBACC FFRDC contract (January 2026).

Luminex competes without geographic or socioeconomic set-asides, winning work through competitive and sole-source justifications grounded in technical specialty and sole-source authority. The company's footprint reflects established market position in federal multiplex diagnostics, equipment maintenance, and reagent supply, with heaviest concentration in DLA medical supply chain logistics and Navy and Air Force health operations.